Literature DB >> 33961708

Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.

Christopher A Lamb1, Shaji Sebastian2, Alexandra J Kent3, Jonathan P Segal3, Haidee A Gonzalez2, Matthew J Brookes4, Shameer J Mehta3, Sreedhar Subramanian5, Neeraj Bhala6, Lucy C Hicks3, Thomas E Conley5, Kamal V Patel3, Gareth J Walker7, Nicholas A Kennedy8.   

Abstract

Entities:  

Year:  2021        PMID： 33961708     DOI： 10.1111/apt.16349

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  3 in total

Review 1.  Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.

Authors:  Long Chen; Kai Hu; Cheng Cheng; Quanman Hu; Liang Zhang; Tongyan An; Yongjun Guo; Shuaiyin Chen; Guangcai Duan
Journal:  Int J Colorectal Dis       Date:  2022-10-22       Impact factor: 2.796

2.  Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis.

Authors:  Fatema Alrashed; Hajer Alasfour; Mohammad Shehab
Journal:  JGH Open       Date:  2022-03-20

3.  Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study.

Authors:  Anna Viola; Marco Muscianisi; Raffaele Li Voti; Giuseppe Costantino; Angela Alibrandi; Walter Fries
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.